Sign up to save your podcasts
Or
Share Episode 1: Surrogate Endpoints in AML
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 1: Surrogate Endpoints in AML
Bernie Marini and Anthony Perissinotti discuss the following paper on whether or not event-free survival (EFS) is an appropriate surrogate endpoint for overall survival (OS) in AML:
Norsworthy KJ, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. J Clin Oncol. 2022 Mar 10;40(8):847-854. PMID: 34890212.
View all episodes
By Bernard Marini, Anthony Perissinotti, et al.
4.5
2828 ratings
Bernie Marini and Anthony Perissinotti discuss the following paper on whether or not event-free survival (EFS) is an appropriate surrogate endpoint for overall survival (OS) in AML:
Norsworthy KJ, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. J Clin Oncol. 2022 Mar 10;40(8):847-854. PMID: 34890212.
More shows like WolverHeme Happy Hour
View all
JAMA Clinical Reviews
498 Listeners
The Hematologist
28 Listeners
OncoPharm
184 Listeners
The Peter Attia Drive
8,187 Listeners
VJHemOnc Podcast
2 Listeners
Plenary Session - inactive due to federal service
756 Listeners
Treating Blood Cancers
12 Listeners
Blood Podcast
53 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Healthcare Unfiltered
136 Listeners
EHA Unplugged
1 Listeners
Blood Cancer Talks
49 Listeners
Two Onc Docs
185 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners
HemeTalks: Conversations in Hematology Education
3 Listeners